Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia

QR Code

Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia

Maju Mathews,1 Srihari Gopal,1 Isaac Nuamah,1 Ludger Hargarter,2 Adam J Savitz,1 Edward Kim,3 Wilson Tan,4 Bernardo Soares,5 Christoph U Correll6–81Department of Neuroscience, Janssen Research & Development, LLC, Raritan, NJ, USA; 2Department of Neuroscience, Janssen-Cilag EMEA, Ne...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Mathews M, Gopal S, Nuamah I, Hargarter L, Savitz AJ, Kim E, Tan W, Soares B, Correll CU
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2019
Sujets:	number-needed-to-harm number-needed-to-treat paliperidone palmitate 3-monthly remission Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Accès en ligne:	https://doaj.org/article/b81367fbed5e43a5b09a55d1a775e7bc
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate
par: Mathews M, et autres
Publié: (2018)

Improvement of Negative Symptoms in Schizophrenia with Paliperidone Palmitate 1-Month and 3-Month Long-Acting Injectables: Results from a Phase 3 Non-Inferiority Study
par: Gopal S, et autres
Publié: (2020)

Effect of Paliperidone Palmitate 3-Month Formulation on Goal Attainment and Disability After 52 Weeks’ Treatment in Patients with Clinically Stable Schizophrenia
par: Lambert M, et autres
Publié: (2020)

Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Hoc Analysis of 3 Similarly Designed Randomized Studies
par: Mathews M, et autres
Publié: (2020)

Long-term efficacy and safety of paliperidone palmitate once-monthly in Chinese patients with recent-onset schizophrenia
par: Si T, et autres
Publié: (2019)

Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study
par: Savitz AJ, et autres
Publié: (2017)

Online Survey of Clinical Practice in Patients with Schizophrenia Treated with Long-Acting Injectable Aripiprazole or Paliperidone Palmitate
par: Such P, et autres
Publié: (2021)

Once-monthly paliperidone palmitate in early stage schizophrenia – a retrospective, non-interventional 1-year study of patients with newly diagnosed schizophrenia
par: Emsley R, et autres
Publié: (2017)

Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation
par: Nash AI, et autres
Publié: (2019)

Efficacy and safety of once-monthly injection of paliperidone palmitate in hospitalized Asian patients with acute exacerbated schizophrenia: an open-label, prospective, noncomparative study
par: Li HF, et autres
Publié: (2015)

Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review
par: Emsley R, et autres
Publié: (2018)

Treatment of Patients with Recently Exacerbated Schizophrenia with Paliperidone Palmitate: A Pilot Study of Efficacy and Tolerability
par: Gattaz WF, et autres
Publié: (2020)

Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study
par: Zhao JP, et autres
Publié: (2017)

Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population
par: Savitz AJ, et autres
Publié: (2019)

Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia
par: Brasso C, et autres
Publié: (2017)

Effectiveness of 1-year treatment with long-acting formulation of aripiprazole, haloperidol, or paliperidone in patients with schizophrenia: retrospective study in a real-world clinical setting
par: Di Lorenzo R, et autres
Publié: (2019)

Availability and use of number needed to treat (NNT) based decision aids for pharmaceutical interventions
par: Cassandra Nguyen, et autres
Publié: (2021)

Assessing effectiveness of aripiprazole lauroxil vs placebo for the treatment of schizophrenia using number needed to treat and number needed to harm
par: Citrome L, et autres
Publié: (2019)

Long-Acting Injectable Drugs in the Maintenance Therapy of Patients with Schizophrenia
par: Natalia N. Petrova, et autres
Publié: (2020)

Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: impact on clinical status, substance craving, and quality of life
par: Cuomo I, et autres
Publié: (2018)

On the (M, D) number of a graph
par: John,J., et autres
Publié: (2019)

Factors related to improvement of symptoms, function, and caregiver burden in Chinese patients with schizophrenia after switching to paliperidone palmitate once-monthly from oral antipsychotics
par: Li N, et autres
Publié: (2018)

Characterization of Upper Detour Monophonic Domination Number
par: Khayyoom,M. Mohammed Abdul
Publié: (2020)

The upper open monophonic number of a graph
par: Santhakumaran,A. P., et autres
Publié: (2014)

The edge-to-edge geodetic domination number of a graph
par: John,J., et autres
Publié: (2021)

Edge Detour Monophonic Number of a Graph
par: Santhakumaran,A. P., et autres
Publié: (2013)

The forcing open monophonic number of a graph
par: Santhakumaran,A. P., et autres
Publié: (2016)

Caregiver burden in schizophrenia following paliperidone palmitate long acting injectables treatment: pooled analysis of two double-blind randomized phase three studies
par: Srihari Gopal, et autres
Publié: (2017)

The total double geodetic number of a graph
par: Santhakumaran,A. P., et autres
Publié: (2020)

Engineering cocrystals of Paliperidone with enhanced solubility and dissolution characteristics
par: Radha-Rani Earle, et autres
Publié: (2021)

Equi independent equitable dominating sets in graphs
par: Vaidya,S. K., et autres
Publié: (2016)

The t-pebbling number of Lamp graphs
par: Lourdusamy,A., et autres
Publié: (2018)

Safety and efficacy of paliperidone extended-release in Chinese patients with schizophrenia: a 24-week, open-label extension of a randomized, double-blind, placebo-controlled study
par: Zhang H, et autres
Publié: (2016)

Comparison of Weight Gain in Injectable Contraceptive 1-Month And 3-Month Acceptors at The Independent Midwife Practice Tambaksari Surabaya
par: Khoiriya Ardiani, et autres
Publié: (2020)

The nonsplit domination in subdivision graph
par: Chrislight,R. Jemimal, et autres
Publié: (2020)

Defining “Adequately Treated”: A Post Hoc Analysis Examining Characteristics of Patients with Schizophrenia Successfully Transitioned from Once-Monthly Paliperidone Palmitate to Once-Every-3-Months Paliperidone Palmitate
par: O'Donnell A, et autres
Publié: (2021)

Finite Sums Involving Reciprocals of the Binomial and Central Binomial Coefficients and Harmonic Numbers
par: Necdet Batir, et autres
Publié: (2021)

Connected edge monophonic number of a graph
par: Santhakumaran,A P, et autres
Publié: (2013)

A qualitative examination of substance use service needs among people who use drugs (PWUD) with treatment and service experience in Ontario, Canada
par: Cayley Russell, et autres
Publié: (2021)

Active Case Finding of Tuberculosis: Randomized Evaluation of Simple and Infotainment Chest Camps
par: Muhammad Amir Khan, et autres
Publié: (2017)